New Strong Buy Stocks for October 29th

ODD, BOOM, BSRR, AIN and MUR have been added to the Zacks Rank #1 (Strong Buy) List on October 29th, 2026.

Zacks Investment Research • 13 hours ago

ODDITY to Announce Third Quarter 2026 Financial Results on November 11, 2026

NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it will release its third quarter 2026 financial results before the market open on Wednesday, November 11, 2026, to be followed by a conference call at 8:30 a.m. Eastern Time.

GlobeNewsWire • Oct 28, 2026

Oddity Tech (ODD) Upgraded to Strong Buy: Here's What You Should Know

Oddity Tech (ODD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research • Oct 15, 2026

New Strong Buy Stocks for October 15th

KMX, ACIC, ONC, ODD and WES have been added to the Zacks Rank #1 (Strong Buy) List on October 15, 2026.

Zacks Investment Research • Oct 15, 2026

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition

NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company's proprietary PD‑L1/4‑1BB bispecific antibody, has been granted Orphan Drug Designation (ODD) by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This is the third Orphan Drug Designation for opamtistomig, following designations in the U.S. Food and Drug Administration (FDA) and the European Commission (EC), marking a further expansion of its global regulatory recognition into a strategically important Asian market.

GlobeNewsWire • Sep 28, 2026

Earnings Estimates Moving Higher for Oddity Tech (ODD): Time to Buy?

Oddity Tech (ODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research • Sep 15, 2026

Oddity Tech: Turnaround Potential And Discounted Debt Value Lever

ODD's turnaround could benefit from improving acquisition costs, even if profitability takes longer to recover than revenue. SpoiledChild is a nice, growing revenue base. And METHODIQ and Labs offer longer-term opportunities beyond IL MAKIAGE's potential recovery. ODD also has convertible bonds trading at a discount and a 0% coupon. This is essentially cheap debt that gives ODD flexibility and an interesting value lever.

Seeking Alpha • Sep 11, 2026

Why Oddity Tech's Stock Skyrocketed 26.5% Today

Oddity Tech's second-quarter sales fell 25% to $181 million, just ahead of Wall Street's target. Earnings fell from $0.92 per share to $0.20, topping analyst estimates by a penny.

The Motley Fool • Sep 9, 2026

ODDITY shares surge on Q2 beat and raised FY26 guidance

ODDITY (NASDAQ:ODD) shares jumped 14% on Thursday after the company posted second-quarter results that topped Wall Street estimates and issued a stronger-than-expected full-year profit outlook. The consumer tech company reported revenue of $181 million for the quarter, beating estimates of $178 million but down 25% from a year earlier.

Proactive Investors • Sep 9, 2026

ODDITY Tech Q2 Earnings Call Highlights

ODDITY Tech NASDAQ: ODD reported second-quarter 2026 net revenue of $181 million, down 25% from a year earlier, as its IL MAKIAGE brand continued to face higher customer-acquisition costs tied to an advertising-account dislocation with its largest ad partner.

MarketBeat • Sep 9, 2026